Back to search
FDAFDA · Food and drugs·Recall number D-0873-2022

Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017

Published May 25, 2022 · Recall initiated: April 22, 2022

Summary

FDA records drug Class II recall D-0873-2022, published May 25, 2022 and initiated April 22, 2022. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 10,304 bottles; Lot: Lots: DX8682 Exp. MAR 31 2023; DG1188 Exp. MAR 31 2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
Nationwide and Puerto Rico
Lot
Lots: DX8682 Exp. MAR 31 2023; DG1188 Exp. MAR 31 2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017 recalled?

Yes. FDA published recall D-0873-2022 on May 25, 2022. Reported hazard: CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release